著者

高井 靖 夏目 優太郎 梶間 勇樹

出版者

一般社団法人 日本老年薬学会

雑誌

日本老年薬学会雑誌 (ISSN:24334065)

巻号頁・発行日

vol.6, no.3, pp.64-70, 2023-09-30 (Released:2023-11-01)

参考文献数

17

---

We conducted a survey to assess changes in dosage of drugs for treatment of heart failure patients. The survey included all patients admitted to the Mie-Heart Center for heart failure treatment between July 2021 and December 2021. We included 80 patients whose medications could be confirmed after one year. The patients were divided into three groups according to LVEF at baseline: HFrEF, HFmrEF, and HFpEF groups. The endpoint was the change in heart failure medication dose at baseline and after 1 year. Dose changes were classified into “no administration”, “same dose”, “increased dose”, “additional dose”, and “reduced dose”. Statistical analysis was performed by cross-tabulation and chi-square test and residual analysis. There were significant differences in MRA for dose change overall (p<0.001) and dose change overall for RA system inhibitors (p=0.001) and SGLT2 inhibitors (p=0.023), and the adjusted residual ʻno dose’ for all three factors was higher in the HFpEF group. Furthermore, there was a significant difference in dose change overall for β-blockers (p=0.005), and the adjusted residual ʻdose increase’ was higher in the HFrEF group. Our findings suggest that there were many patients in the HFrEF group who continued to take MRA and RA system inhibitors at the induction dose and increased the dose of β-blockers, suggesting a tendency by medical staff to administer additional SGLT2 inhibitors.